Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon
Marna G. Bouwhuis(Erasmus MC), Sandra Collette(University of Turin), Cornelis J.A. Punt(Utrecht University), Poulam M. Patel(Nottingham University Hospitals NHS Trust), Ulrika Stierner(University of Gothenburg), Alexander M.M. Eggermont(University Medical Center Utrecht), Lars Bastholt(Odense University Hospital), Steinar Aamdal(Humboldt-Universität zu Berlin), Micaela Hernberg(Apple (Israel)), Stefan Suciu(St James's University Hospital), Timo L.M. ten Hagen(Erasmus MC), François Salès(Institut Jules Bordet), Johan Hansson(Mid Sweden University), Alan Spatz(Jewish General Hospital), Wim H.J. Kruit(Erasmus MC)
Cited by 73
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k